{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:38:31Z","timestamp":1791308311135,"version":"4.3.1"},"reference-count":58,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swedish Cancer Society","award":["20 0815, 21 1485 Pj"],"award-info":[{"award-number":["20 0815, 21 1485 Pj"]}]},{"name":"Swedish Cancer Society","award":["VR 2019-00986"],"award-info":[{"award-number":["VR 2019-00986"]}]},{"name":"Swedish Cancer Society","award":["2019-00994"],"award-info":[{"award-number":["2019-00994"]}]},{"name":"Swedish Cancer Society","award":["075-15-2022-1103"],"award-info":[{"award-number":["075-15-2022-1103"]}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["20 0815, 21 1485 Pj"],"award-info":[{"award-number":["20 0815, 21 1485 Pj"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["VR 2019-00986"],"award-info":[{"award-number":["VR 2019-00986"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2019-00994"],"award-info":[{"award-number":["2019-00994"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["075-15-2022-1103"],"award-info":[{"award-number":["075-15-2022-1103"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science and Higher Education","award":["20 0815, 21 1485 Pj"],"award-info":[{"award-number":["20 0815, 21 1485 Pj"]}]},{"name":"Ministry of Science and Higher Education","award":["VR 2019-00986"],"award-info":[{"award-number":["VR 2019-00986"]}]},{"name":"Ministry of Science and Higher Education","award":["2019-00994"],"award-info":[{"award-number":["2019-00994"]}]},{"name":"Ministry of Science and Higher Education","award":["075-15-2022-1103"],"award-info":[{"award-number":["075-15-2022-1103"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Radionuclide molecular imaging could provide an accurate assessment of the expression of molecular targets in disseminated cancers enabling stratification of patients for specific therapies. B7-H3 (CD276) is a transmembrane protein belonging to the B7 superfamily. This protein is overexpressed in different types of human malignancies and such upregulation is generally associated with a poor clinical prognosis. In this study, targeting properties of an Affibody-based probe, AC12, containing a -GGGC amino acid sequence as a chelator (designated as AC12-GGGC) labelled with technetium-99m (99mTc) were evaluated for imaging of B7-H3-expressing tumours. AC12-GGGC was efficiently labelled with 99mTc. [99mTc]Tc-AC12-GGGC bound specifically to B7-H3 expressing cells in vitro with affinities in nanomolar range. In mice bearing B7-H3-expressing xenografts, [99mTc]Tc-AC12-GGGC showed tumour uptake of 2.1 \u00b1 0.5 %ID\/g at 2 h after injection. Its clearance from blood, normal organs and tissues was very rapid. This new targeting agent, [99mTc]Tc-AC12-GGGC, provided high tumour-to-blood ratio already at 2 h (8.2 \u00b1 1.9), which increased to 11.0 \u00b1 0.5 at 4 h after injection. Significantly (p &lt; 0.05) higher tumour-to-liver and higher tumour-to-bone ratios at 2 h in comparison with 4 h after injection were observed. Thus, [99mTc]Tc-AC12-GGGC could be a promising candidate for further development.<\/jats:p>","DOI":"10.3390\/pharmaceutics14091780","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T02:04:32Z","timestamp":1661479472000},"page":"1780","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of an Affibody-Based Binder for Imaging of Immune Check-Point Molecule B7-H3"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2660-9837","authenticated-orcid":false,"given":"Maryam","family":"Oroujeni","sequence":"first","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden"},{"name":"Affibody AB, 171 65 Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-5719","authenticated-orcid":false,"given":"Ekaterina A.","family":"Bezverkhniaia","sequence":"additional","affiliation":[{"name":"Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia"},{"name":"Scientific and Research Laboratory of Chemical and Pharmaceutical Research, Siberian State Medical University, 634050 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1826-4093","authenticated-orcid":false,"given":"Tianqi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5871-5779","authenticated-orcid":false,"given":"Yongsheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4374-6422","authenticated-orcid":false,"given":"Evgenii V.","family":"Plotnikov","sequence":"additional","affiliation":[{"name":"Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2297-3877","authenticated-orcid":false,"given":"Ida","family":"Karlberg","sequence":"additional","affiliation":[{"name":"Affibody AB, 171 65 Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ryer","sequence":"additional","affiliation":[{"name":"Affibody AB, 171 65 Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6120-2683","authenticated-orcid":false,"given":"Anna","family":"Orlova","sequence":"additional","affiliation":[{"name":"Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia"},{"name":"Department of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-1734","authenticated-orcid":false,"given":"Vladimir","family":"Tolmachev","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden"},{"name":"Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-4142","authenticated-orcid":false,"given":"Fredrik Y.","family":"Frejd","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden"},{"name":"Affibody AB, 171 65 Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/85339","article-title":"B7-H3: A costimulatory molecule for T cell activation and IFN-\u03b3 production","volume":"2","author":"Chapoval","year":"2001","journal-title":"Nat. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.4049\/jimmunol.172.4.2352","article-title":"Molecular Characterization of Human 4Ig-B7-H3, a Member of the B7 Family with Four Ig-Like Domains","volume":"172","author":"Steinberger","year":"2004","journal-title":"J. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.4049\/jimmunol.168.12.6294","article-title":"Characterization of Mouse and Human B7-H3 Genes","volume":"168","author":"Sun","year":"2002","journal-title":"J. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/156800908785133141","article-title":"The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion","volume":"8","author":"Chen","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10277","DOI":"10.1073\/pnas.0805458105","article-title":"The contrasting role of B7-H3","volume":"105","author":"Hofmeyer","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1158\/0008-5472.CAN-08-4517","article-title":"MicroRNA miR-29 Modulates Expression of Immunoinhibitory Molecule B7-H3: Potential Implications for Immune Based Therapy of Human Solid Tumors","volume":"69","author":"Xu","year":"2009","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1158\/0008-5472.CAN-07-1068","article-title":"B7-H3 Ligand Expression by Prostate Cancer: A Novel Marker of Prognosis and Potential Target for Therapy","volume":"67","author":"Roth","year":"2007","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"19458","DOI":"10.1073\/pnas.0709802104","article-title":"B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome","volume":"104","author":"Zang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1158\/1078-0432.CCR-08-0536","article-title":"Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma","volume":"14","author":"Crispen","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1158\/1078-0432.CCR-08-0731","article-title":"T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival","volume":"14","author":"Boorjian","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/modpathol.2010.95","article-title":"Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas","volume":"23","author":"Zang","year":"2010","journal-title":"Mod. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1158\/1078-0432.CCR-11-0880","article-title":"Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness","volume":"18","author":"Lemke","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wang, L., Zhang, Q., Chen, W., Shan, B., Ding, Y., Zhang, G., Cao, N., Liu, L., and Zhang, Y. (2013). B7-H3 is Overexpressed in Patients Suffering Osteosarcoma and Associated with Tumor Aggressiveness and Metastasis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0070689"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/sj.bjc.6605375","article-title":"Clinical importance of B7-H3 expression in human pancreatic cancer","volume":"101","author":"Yamato","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2559.2008.03070.x","article-title":"Small round blue cell tumours: Diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule","volume":"53","author":"Gregorio","year":"2008","journal-title":"Histopathology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-012-1021-2","article-title":"B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma","volume":"111","author":"Zhou","year":"2013","journal-title":"J. Neuro-Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1002\/jcp.22600","article-title":"Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: Immunotherapeutic implications","volume":"226","author":"Sigalotti","year":"2011","journal-title":"J. Cell. Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ygyno.2011.09.012","article-title":"Immunoexpression of B7-H3 in endometrial cancer: Relation to tumor T-cell infiltration and prognosis","volume":"124","author":"Brunner","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/ijc.27566","article-title":"B7-H3 expression in colorectal cancer: Nuclear localization strongly predicts poor outcome in colon cancer","volume":"131","author":"Ingebrigtsen","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s00262-012-1278-5","article-title":"B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence","volume":"61","author":"Sun","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1073\/pnas.1516991112","article-title":"Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response","volume":"112","author":"Chen","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3892\/or.2016.4607","article-title":"B7-H3, B7-H4, Foxp3 and IL-2 expression in cervical cancer: Associations with patient outcome and clinical significance","volume":"35","author":"Huang","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lungcan.2016.11.013","article-title":"Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis","volume":"103","author":"Inamura","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/apm.12837","article-title":"B7-H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma","volume":"126","author":"Cheng","year":"2018","journal-title":"Apmis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"27528","DOI":"10.1038\/srep27528","article-title":"Soluble B7-H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4\/NF-\u03baB pathway","volume":"6","author":"Xie","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.7150\/thno.25575","article-title":"Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a","volume":"8","author":"Burvenich","year":"2018","journal-title":"Theranostics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nucmedbio.2017.12.004","article-title":"212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models","volume":"58","author":"Kasten","year":"2018","journal-title":"Nucl. Med. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1200\/JCO.20.01974","article-title":"B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study","volume":"38","author":"Modak","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MNM.0b013e3282f3a515","article-title":"PET versus SPECT: Strengths, limitations and challenges","volume":"29","author":"Rahmim","year":"2008","journal-title":"Nucl. Med. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.pcad.2015.02.002","article-title":"Advances in SPECT and PET Hardware","volume":"57","author":"Slomka","year":"2015","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.nucmedbio.2020.05.005","article-title":"Review on 99mTc radiopharmaceuticals with emphasis on new advancements","volume":"92","author":"Duatti","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ymeth.2013.09.015","article-title":"Engineered antibodies for molecular imaging of cancer","volume":"65","author":"Wu","year":"2014","journal-title":"Methods"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.molimm.2015.04.001","article-title":"In vivo imaging with antibodies and engineered fragments","volume":"67","author":"Freise","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.18632\/oncotarget.13910","article-title":"Quantitative assessment of Zirconium-89 labeled cetuximab using PET\/CT imaging in patients with advanced head and neck cancer: A theragnostic approach","volume":"8","author":"Even","year":"2017","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2967\/jnumed.117.199901","article-title":"Same-day imaging using small proteins: Clinical experience and translational prospects in oncology","volume":"59","author":"Krasniqi","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","article-title":"Affibody Molecules in Biotechnological and Medical Applications","volume":"35","author":"Frejd","year":"2017","journal-title":"Trends Biotechnol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Tolmachev, V., and Orlova, A. (2020). Affibody Molecules as Targeting Vectors for PET Imaging. Cancers, 12.","DOI":"10.3390\/cancers12030651"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2967\/jnumed.113.131243","article-title":"First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule","volume":"55","author":"Sandberg","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7150\/thno.13502","article-title":"Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET\/CT","volume":"6","author":"Velikyan","year":"2016","journal-title":"Theranostics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1021\/acscombsci.8b00156","article-title":"Cellular-Based Selections Aid Yeast-Display Discovery of Genuine Cell-Binding Ligands: Targeting Oncology Vascular Biomarker CD276","volume":"21","author":"Stern","year":"2019","journal-title":"ACS Comb. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1158\/1078-0432.CCR-19-1655","article-title":"Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection","volume":"26","author":"Bam","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2967\/jnumed.110.083592","article-title":"Molecular Design and Optimization of 99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties","volume":"52","author":"Orlova","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00726-011-0927-x","article-title":"Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules","volume":"42","author":"Altai","year":"2012","journal-title":"Amino Acids"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Oroujeni, M., Rinne, S., Vorobyeva, A., Loftenius, A., Feldwisch, J., Jonasson, P., Chernov, V., Orlova, A., Frejd, F., and Tolmachev, V. (2021). Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052770"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.nucmedbio.2010.02.009","article-title":"Kit formulation for 99mTc-labelling of recombinant anti-HER2 affibody molecules with a C-terminally engineered cysteine","volume":"37","author":"Ahlgren","year":"2010","journal-title":"Nucl. Med. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.apradiso.2006.03.002","article-title":"Automated, high-resolution cellular retention and uptake studies in vitro","volume":"64","author":"Andersson","year":"2006","journal-title":"Appl. Radiat. Isot."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bbrc.2012.10.008","article-title":"Deciphering complex protein interaction kinetics using Interaction Map","volume":"428","author":"Altschuh","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41181-020-00094-w","article-title":"Imaging using radiolabelled targeted proteins: Radioimmunodetection and beyond","volume":"5","author":"Garousi","year":"2020","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2967\/jnumed.108.056929","article-title":"Targeting of HER2-expressing tumours with a site-specifically 99mTc-labeled recombinant Affibody molecule, ZHER2:2395, with C-terminally engineered cysteine","volume":"50","author":"Ahlgren","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2967\/jnumed.111.101527","article-title":"Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition","volume":"53","author":"Tolmachev","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3892\/or.2015.4046","article-title":"Comparative evaluation of 111In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors","volume":"34","author":"Andersson","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1021\/acs.molpharmaceut.6b00502","article-title":"Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX","volume":"13","author":"Garousi","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_54","first-page":"1967","article-title":"68Ga-DOTA-Affibody molecule for in vivo assessment of HER2\/neu expression with PET","volume":"38","author":"Shenoy","year":"2011","journal-title":"Eur. J. Pediatr."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/0008-5472.CAN-05-3521","article-title":"Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule","volume":"66","author":"Orlova","year":"2006","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1038\/s41598-019-51445-w","article-title":"Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts","volume":"9","author":"Garousi","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_57","first-page":"231","article-title":"Differences in Biodistribution Between 99mTc-Depreotide, 111In-DTPA-Octreotide, and 177Lu-DOTA-Tyr3-Octreotate in a Small Cell Lung Cancer Animal Model","volume":"20","author":"Schmitt","year":"2005","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.bmc.2013.12.063","article-title":"Design, synthesis and biological evaluation of negatively charged 111In-DTPA-octreotide derivatives","volume":"22","author":"Oshima","year":"2014","journal-title":"Bioorg. Med. Chem."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/9\/1780\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:15:21Z","timestamp":1760141721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/9\/1780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":58,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["pharmaceutics14091780"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14091780","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}